Earnings Feed
Start Free
Home/Filings/4/0000929638-23-002987
4//SEC Filing

Glickman Richard M 4

Accession 0000929638-23-002987

CIK 0001980845other
View on SEC.govCompany Profile

Filed

Nov 1, 8:00 PM ET

Accepted

Nov 2, 4:08 PM ET

Size

24.6 KB

Accession

0000929638-23-002987

Insider Transaction Report

Form 4
Period: 2023-10-31
enGene Holdings Inc.ENGN
Glickman Richard M
Director
Transactions
  • Award

    Common Shares

    2023-10-31+24,555→ 24,555 total
  • Award

    Stock Option (Right to Buy)

    2013-12-04+120→ 120 total
    Exercise: $0.88Exp: 2023-12-04→ Common Shares (120 underlying)
  • Award

    Stock Option (Right to Buy)

    2021-08-20+12,001→ 12,001 total
    Exercise: $0.88Exp: 2031-08-20→ Common Shares (12,001 underlying)
  • Award

    Stock Option (Right to Buy)

    2015-05-21+11,189→ 11,189 total
    Exercise: $0.88Exp: 2025-05-21→ Common Shares (11,189 underlying)
  • Award

    Stock Option (Right to Buy)

    2016-01-11+9,023→ 9,023 total
    Exercise: $0.88Exp: 2026-01-11→ Common Shares (9,023 underlying)
  • Award

    Stock Option (Right to Buy)

    2017-06-15+3,188→ 3,188 total
    Exercise: $0.88Exp: 2027-06-15→ Common Shares (3,188 underlying)
  • Award

    Stock Option (Right to Buy)

    2018-03-16+4,123→ 4,123 total
    Exercise: $0.88Exp: 2028-03-16→ Common Shares (4,123 underlying)
  • Award

    Stock Option (Right to Buy)

    2020-12-14+12,032→ 12,032 total
    Exercise: $0.88Exp: 2030-12-14→ Common Shares (12,032 underlying)
  • Award

    Stock Option (Right to Buy)

    2021-08-20+14,205→ 14,205 total
    Exercise: $0.88Exp: 2031-08-20→ Common Shares (14,205 underlying)
Footnotes (11)
  • [F1]On October 31, 2023 (the "Closing Date"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the "Business Combination Agreement"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation ("FEAC"), enGene Inc., a corporation incorporated under the laws of Canada ("enGene"), and enGene Holdings Inc. (the "Issuer" or "New enGene"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene. The transactions contemplated by the Business Combination Agreement are referred to herein as the "Business Combination".
  • [F10]This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 78,712 common shares of enGene.
  • [F11]This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 66,500 common shares of enGene.
  • [F2]Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer ("Common Shares") for each share of enGene held by them immediately prior to the Closing Date. Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended.
  • [F3]Reflects Common Shares acquired pursuant to the Business Combination.
  • [F4]This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 667 common shares of enGene.
  • [F5]This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 62,000 common shares of enGene.
  • [F6]This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 50,000 common shares of enGene.
  • [F7]This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 17,668 common shares of enGene.
  • [F8]This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 22,848 common shares of enGene.
  • [F9]This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 66,667 common shares of enGene.

Documents

1 file

Issuer

enGene Holdings Inc.

CIK 0001980845

→
Entity typeother

Related Parties

1
  • filerCIK 0001352637

Filing Metadata

Form type
4
Filed
Nov 1, 8:00 PM ET
Accepted
Nov 2, 4:08 PM ET
Size
24.6 KB
View on SEC.gov